PRO-ACT|ALS研究数据集|临床试验数据集

The PRO-ACT platform houses the largest ALS clinical trials dataset ever created. It is a powerful tool for biomedical researchers, statisticians, clinicians, or anyone else interested in "Big Data." PRO-ACT merges data from existing public and private clinical trials, generating an invaluable resource for the design of future ALS clinical trials. The database will also contribute to the identification of unique observations, novel correlations, and patterns of ALS disease progression, as well as a variety of still unconsidered analyses. More than 600,000 people around them world are battling ALS. The disease strikes indiscriminately, and typically patients will die within 2-5 years following diagnosis. Currently, there are no effective treatments or a cure for ALS. Users of PRO-ACT are helping to accelerate the discovery, development, and delivery of ALS treatments, which will provide hope to patients and their families.

PRO-ACT 平台汇聚了迄今为止所创建的最大规模的 ALS 临床试验数据集。该平台是一项强大的工具，对生物医学研究者、统计学家、临床医生或任何对大数据感兴趣的个人而言至关重要。PRO-ACT 通过整合现有公共和私人临床试验的数据，为未来 ALS 临床试验的设计提供了一个无价的资源。该数据库还将有助于识别独特的观察结果、新颖的相关性和 ALS 疾病进展的模式，以及多种尚未考虑的复杂分析。全球范围内，超过 60 万人正在与 ALS 作斗争。该疾病无差别地侵袭，患者通常在确诊后 2-5 年内去世。目前，尚无有效的治疗手段或治愈方法。PRO-ACT 的用户正在协助加速 ALS 治疗的发现、开发和交付，为患者及其家人带来希望。